...
首页> 外文期刊>Journal of enzyme inhibition and medicinal chemistry. >A nanobody-derived mimotope against VEGF inhibits cancer angiogenesis
【24h】

A nanobody-derived mimotope against VEGF inhibits cancer angiogenesis

机译:针对VEGF的纳米甲型衍生的模拟物抑制癌症血管生成

获取原文
           

摘要

Vascular Endothelial Growth Factor (VEGF) promotes angiogenesis in tumours of various cancers. Monoclonal antibodies and nanobodies are one of the potent agents in the treatment of cancer. Due to their high costs, researchers are considering to design and produce peptides as a substitute approach in recent years. The aim of the current study was designing a mimotope against VEGF and evaluate its effects on cell proliferation and tube formation in the HUVEC cell line. For this, a peptide was designed against VEGF and chemically produced. The effects of synthetic peptide and nanobody on the inhibition of proliferation of HUVEC cells were examined using MTT and tube formation assays. The data indicate that the peptide was able to significantly inhibit both HUVEC cell proliferation and tube formation through inhibition of VEGF, highlighting the potential of peptides as a ‘novel’ class of candidate drugs to inhibit angiogenesis.
机译:血管内皮生长因子(VEGF)促进各种癌症的肿瘤中的血管生成。单克隆抗体和纳米抗体是治疗癌症的有效剂之一。由于其高成本,研究人员正在考虑近年来设计和生产肽作为替代方法。目前研究的目的是设计反对VEGF的模仿,评价其对Huvec细胞系中细胞增殖和管形成的影响。为此,肽设计针对VEGF并进行化学制作。使用MTT和管形成测定检查合成肽和纳米谱对抑制Huvec细胞增殖的抑制作用。这些数据表明,通过抑制VEGF,肽能够显着抑制Huvec细胞增殖和管形成,突出肽作为“新颖”候选药物来抑制血管生成的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号